Review

Islet Transplantation and Encapsulation: An Update on Recent Developments

Vijayaganapathy Vaithilingam, Bernard E. Tuch

Manuscript submitted April 14, 2011; resubmitted May 2, 2011; accepted May 5, 2011.

Keywords: alginate poly-l-lysine, islet transplantation, pericapsular fibrotic overgrowth, sulphated glucomannan-barium-alginate, encapsulation, microcapsules

Abstract

Human islet transplantation can provide good glycemic control in diabetic recipients without exogenous insulin. However, a major factor limiting its application is the recipient's need to adhere to life-long immunosuppression, something that has serious side effects. Microencapsulating human islets is a strategy that should prevent rejection of the grafted tissue without the need for anti-rejection drugs. Despite promising studies in various animal models, the encapsulated human islets so far have not made an impact in the clinical setting. Many non-immunological and immunological factors such as biocompatibility, reduced immunoprotection, hypoxia, pericapsular fibrotic overgrowth, effects of the encapsulation process and post-transplant inflammation hamper the successful application of this promising technology. In this review, strategies are discussed to overcome the above-mentioned factors and to enhance the survival and function of encapsulated insulin-producing cells, whether in islets or surrogate β-cells. Studies at our center show that barium alginate microcapsules are biocompatible in rodents, but not in humans, raising concerns over the use of rodents to predict outcomes. Studies at our center also show that the encapsulation process had little or no effect on the cellular transcriptome of human islets and on their ability to function either in vitro or in vivo. New approaches incorporating further modifications to the microcapsule surface to prevent fibrotic overgrowth are vital, if encapsulated human islets or β-cell surrogates are to become a viable therapy option for type 1 diabetes in humans.

Fulltext: HTML , PDF (567KB)

This article has been cited by other articles:

	Immobilization in biotechnology and biorecognition: from macro- to nanoscale systems Bucko M, Mislovicova D, Nahalka J, Vikartovska A, Sefcovicova J, Katrlik J, Tkac J, Gemeiner P, Lacik I, Stefuca V, Polakovic M, Rosenberg M, Rebros M, Smogrovicova D, Svitel J Chem Papers 2012. 66(11):983-998
	Update on islet transplantation McCall M, James Shapiro AM Cold Spring Harb Perspect Med 2012. 2(7):a007823
	Making β cells from adult tissues Efrat S, Russ HA Trends Endocrinol Metab 2012. 23(6):278-285
	Suitability of polyelectrolyte shells modified with fullerene derivate for immunoisolation of cells Borkowska M, Godlewska E, Antosiak-Iwanska M, Kinasiewicz J, Strawski M, Szklarczyk M, Granicka LH J Biomed Nanotech 2012. 8(6): 912-917
	Immunosuppression-free transplantation reconsidered from a regenerative medicine perspective Orlando G Expert Rev Clin Immunol 2012. 8(2):179-187
	Cell therapy in type 1 diabetes Gioviale MC, Bellavia M, Damiano G, Buscemi G J Stem Cell Res Ther 2011. S2:4